Neeland, Linge, and Birkenfeld (2024), writing in Diabetes, Obesity and Metabolism , conclude that skeletal muscle changes with GLP-1 receptor agonist treatment appear adaptive: reductions in muscle volume are commensurate with what is expected given aging, disease status, and weight loss achieved, and improvements in insulin sensitivity and muscle fat infiltration likely contribute to improved muscle quality
However, these treatments can also be harsh on the skin and may cause redness, peeling, and sensitivity
This is generally a long-term treatment solution, and there are precise instructions that you need to follow if you want to see improvements in your diabetes management
Regarding the risk of thyroid cancer, it was clarified that the black box warning and contraindication for the use of GLP-1 apply only to individuals with a personal or family history of medullary thyroid cancer or MEN 2, without the need for additional testing such as TSH or thyroid ultrasound
injections of liraglutide at a dose of 200 g/kg of body weight